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Abstract As tocilizumab (TCZ) greatly inhibits inflam-
matory markers, methods of evaluating rheumatoid arthritis
(RA) disease activity that include inflammatory markers
may overestimate the effect of TCZ treatment. We have
evaluated the impact of inflammatory markers on the effi-
cacy of TCZ by comparing the efficacy indicated by the 28-
joint disease activity score using erythrocyte sedimentation
rate (DAS28-ESR) with that indicated by the clinical and
simplified disease activity indexes (CDAI and SDAI,
respectively) and the American College of Rheumatology
(ACR) core set criteria in a double-blind study of TCZ—
the SATORI study. The Spearman correlation coefficient
between DAS28-ESR and CDAI was comparable between
that at week 24 and that at baseline [correlation coefficient
at baseline and week 24 was 0.823 (p \ 0.0001) and 0.818
(p \ 0.0001), respectively]. A large difference between the
DAS28 remission rate and CDAI remission rate was
observed at week 24. However, these results are compa-
rable to those of a previous study conducted with non-
TCZ-treated patients. Moreover, the same results were
obtained in the comparison between the DAS28-ESR and
SDAI, even though the SDAI includes an inflammatory
parameter as a component. These results confirm that the
DAS28-ESR has a validity comparable to that of other
methods in terms of evaluating the RA treatment efficacy
of TCZ, despite its strong inflammatory marker-inhibiting
effects.
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Introduction
Tocilizumab (TCZ) is a monoclonal anti-interleukin-6
(IL-6) receptor antibody that binds to cell membrane-
bound IL-6 receptors and to free soluble IL-6 receptors in the
serum, thereby blocking IL-6 signalling into cells [1]. This
drug was developed to treat patients with rheumatoid
arthritis (RA), Castleman’s disease and juvenile idiopathic
arthritis, and has been approved as a treatment for these
indications in Japan [2–9]. It has been reported that treatment
with TCZ alone or in combination with disease-modifying
antirheumatic drugs (DMARDs), including methotrexate
(MTX), has therapeutic effects in RA patients who had
an inadequate response to anti-tumour necrosis factor (TNF)
therapy or non-biologic DMARDs or in those who are MTX
naive or had an inadequate response to MTX [2–13].
TCZ directly inhibits the production of acute phase
proteins, such as C-reactive protein (CRP) and fibrinogen
from hepatocytes, by directly inhibiting the action of IL-6.
Consequently, the CRP level and erythrocyte sedimenta-
tion rate (ESR) rapidly and intensively decrease with the
initiation of TCZ treatment before any improvement in
swollen or tender joint counts (TJCs) is observed [14],
possibly resulting in a discrepancy between an improve-
ment in inflammatory markers and an improvement in
actual RA disease activity. This has led to concern among
clinicians on the possibility that methods of evaluating RA
disease activity that include CRP and ESR may overstate
the therapeutic effect of TCZ treatment for RA compared
to methods that do not.
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To investigate the validity of the 28-joint Disease
Activity Score using ESR (DAS28-ESR) for evaluating the
efficacy of TCZ as a treatment for RA, we compared the
efficacy assessment in the SATORI study (a double-blind,
comparative study of TCZ conducted in Japan) [4] using
the DAS28-ESR [15] with the efficacy assessments using
the clinical disease activity index (CDAI) [16], simplified
disease activity index (SDAI) [17] and American College
of Rheumatology (ACR) response [18].
Patients and methods
Patients
This study was based on data from the SATORI study that has
been previously published [4]. The inclusion and exclusion
criteria for enrolment in the SATORI study were as follows.
Eligible patients were between 20 and 75 years old, fulfilled
the ACR (formerly, the American Rheumatism Association)
1987 revised criteria for the classification of RA and had
disease duration[6 months. All candidates had been treated
with MTX (8 mg/week) for at least 8 weeks prior to enrol-
ment but showed an inadequate response to MTX at enrol-
ment by the persistence of active disease, defined as C6 tender
joints (of 49 evaluated), C6 swollen joints (of 46 evaluated)
and ESR C 30 mm/h or CRP C 10 mg/L. Patients were
excluded if, immediately prior to the initiation of TCZ
treatment (start of study), they had received anti-TNF agents
or leflunomide within 12 weeks, plasma exchange therapy or
surgical treatment within 4 weeks, or DMARDs other than
MTX or immunosuppressants within 2 weeks. Patients who
had received oral corticosteroids (B10 mg/day prednisolone)
were enrolled if the dosage had not been changed within the
2 week period immediately preceding the start of TCZ
treatment. Eligible patients had a white blood cell count
C3.5 9 109/L, a lymphocyte count C0.5 9 109/L or a
platelet count of at least the lower limit of normal as defined
by the local laboratory used for all analyses. Patients were
excluded if they were functional class IV according to
Steinbrocker’s criteria [19], had aspartate transaminase, ala-
nine transaminase or serum creatinine C1.5 times the upper
limit of normal, were positive for hepatitis B surface antigen
and/or hepatitis C virus antibody, had pulmonary fibrosis or
active pulmonary disease, had a history of serious adverse
drug reaction to MTX, had concomitant pleural effusion,
ascites or varicella infection or were excessive users of
alcohol on a regular basis. Patients were excluded if they had a
history of serious allergic reaction, or if they had significant
cardiac, blood, respiratory system, neurologic, endocrine,
renal, hepatic or gastrointestinal disease or an active infection
requiring medication within 4 weeks before the start of
treatment. Sexually active premenopausal women were
required to have a negative urine pregnancy test result at the
time of entry to the study and to use effective contraception
throughout the study period.
Protocol
The following is a summary of the protocol of the SATORI
study [4]. This trial is registered at http://www.
clinicaltrials.gov (NCT00144521). The first patient was
enrolled on 27 January 2004, and the last patient exited the
study on 15 February 2005. Patients were randomly assigned
to receive one of the following treatments for 24 weeks:
(1) TCZ (8 mg/kg) once every 4 weeks plus MTX placebo
(TCZ group); (2) or TCZ placebo plus MTX 8 mg/week
(control group). Randomization was achieved by centralized
allocation at a patient enrolment center. The dosage of TCZ
used in this study was chosen based on the results of an
earlier dose-finding study; the dose of MTX was the maxi-
mum dose allowed in Japan. Oral corticosteroids equivalent
to \10 mg/day prednisolone were allowed, but the dose
could not be increased during the study. Intra-articular
injections of corticosteroid (only one joint at one treatment)
and hyaluronate preparations were allowed. The use of one
nonsteroidal anti-inflammatory drug (NSAID), including
switching to another NSAID, was allowed. DMARDs,
intravenous or intramuscular corticosteroids, plasmaphere-
sis and surgical treatment were not allowed.
Efficacy evaluation
Efficacy was evaluated every 4 weeks by calculating the
DAS28-ESR, CDAI and SDAI scores and the ACR response
category. Changes in DAS28-ESR, CDAI and SDAI from
baseline to week 24 were also calculated, and the DAS28-
ESR and ACR response categories were compared qualita-
tively [20]. Remission was evaluated using the following
remission criteria, and the results were compared: DAS28-
ESR \ 2.6; SDAI B 3.3; CDAI B 2.8 [21–23]. ACR20,
ACR50 and ACR70 responses are defined as 20, 50 and 70%
improvement, respectively, in the tender joint count (TJC)
and swollen joint count (SJC), and 20, 50 and 70%
improvement, respectively, in at least three of the following
five parameters: (1) patient self-assessed function (health
assessment questionnaire); (2) patient global assessment
(PGA); (3) physician global assessment (MDGA); (4)
patient pain assessment; (5) either ESR or CRP.
The following formulae were used to calculate DAS28-
ESR, SDAI and CDAI, respectively: (1) DAS28-ESR =
0.56 HTJC ? 0.28 HSJC ? 0.70 ln(ESR) ? 0.014 PGA
(mm); (2) SDAI = SJC ? TJC ? PGA (cm) ? MDGA
(cm) ? CRP (mg/dL); (3) CDAI = SJC ? TJC ? PGA
(cm) ? MDGA (cm), where SJC and TJC are the respec-
tive counts for 28 joints.
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Statistical analysis
Change in continuous variables (DAS28-ESR, CDAI and
SDAI) is amenable to simple linear regression analysis;
therefore, the latter two variables were compared by linear
regression with DAS28-ESR as the independent variable. The
probability of a significant association between the indepen-
dent and dependent variables was defined as p \ 0.05.
Results
Time courses of disease activity scores and their
components
Fifty-three of the 61 patients enrolled in the TCZ-treatment
group in the SATORI study completed the study (24
weeks), and disease activity was measured in 53 patients at
various time points. Figure 1 shows the time courses of the
DAS28-ESR, CDAI and SDAI values and each of the
evaluation items used to calculate these indices. DAS28-
ESR tended to progressively improve during the TCZ
treatment, with the mean DAS28-ESR improving from
6.06 at baseline to 2.77 at week 24. The CDAI and SDAI
also progressively improved during the TCZ treatment.
Furthermore, each of the evaluation items, with the
exception of ESR and CRP, used to calculate DAS28-ESR,
CDAI and SDAI progressively improved during the TCZ
treatment. Conversely, the ESR and CRP levels rapidly
decreased from week 0 to week 4, following which they
remained approximately constant (Fig. 1). At week 24,
joint swelling in the 28 joints of the DAS28 had completely
improved (i.e., SJC = 0) in 13 patients (24.5%), and joint
tenderness had completely improved (i.e., TJC = 0) in 20
patients (37.7%). The sum of the SJC and TJC at week 24
was B1 in 13 patients (24.5%).
Fig. 1 Change in the indices of rheumatoid arthritis (RA) disease
activity and in the variables used to calculate those indices over the
24-week study. The indices and variables shown are the 28-joint
disease activity score using erythrocyte sedimentation rate (DAS28-
ESR), the clinical and simplified disease activity indices (CDAI and
SDAI, respectively), 28-joint swollen and tender joint counts (SJC28
and TJC28, respectively), visual analog scale (VAS) of patient and
physician global assessment (PGA and MDGA, respectively),
C-reactive protein (CRP) and ESR. The treatment received was
either tocilizumab (TCZ) or methotrexate (MTX). Mean values and
standard deviations are shown. The data of the TCZ group and control
group are shown as mean values among the 53 TCZ patients and 37
MTX patients who completed the 24-week study
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Correlations between DAS28-ESR and CDAI or SDAI,
and between DAS28-CRP and CDAI or SDAI
Figure 2a is a scatter plot of the results for each patient in
the TCZ group and shows the correlations between
DAS28-ESR and CDAI at baseline and at week 24, and
between the change in DAS28-ESR and change in CDAI
from baseline to week 24. The Spearman coefficient of
correlation between DAS28-ESR and CDAI at week 24
was 0.823 (p \ 0.0001), which was comparable to that at
Fig. 2 Scatter plots of DAS28-ESR/DAS28-CRP versus CDAI/SDAI
at baseline and at week 24, and change in DAS28-ESR/DAS28-CRP
versus change in CDAI/SDAI at week 24 in the TCZ group. The results
of the 61 patients at baseline and the 53 patients who completed the
24-week study in the TCZ group are shown. All regression lines indicate
a highly significant correlation between DAS28-ESR/DAS28-CRP
and CDAI/SDAI. a DAS28-ESR vs. CDAI, b DAS28-ESR vs. SDAI,
c DAS28-CRP vs. CDAI, d DAS28-CRP vs. SDAI
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baseline (0.818, p \ 0.0001). The coefficient of correlation
between the change in DAS28-ESR and change in CDAI
from baseline to week 24 was 0.772 (p \ 0.0001).
The Spearman coefficient of correlation between
DAS28-ESR and SDAI at week 24 was 0.838 (p \ 0.0001),
which was comparable to that at baseline (0.854, p \ 0.0001).
The coefficient of correlation between the change in DAS28-
ESR and the change in SDAI from baseline to week 24 was
0.803 (p \ 0.0001) (Fig. 2b).
Because the DAS28-CRP is also frequently used to
evaluate the disease activity of RA and because the CRP
level is also considerably decreased by TCZ, a similar
analysis was performed between DAS28-CRP and CDAI
as well as between DAS28-CRP and SDAI. As shown in
the Fig. 2c and d, the results were essentially the same as
those between the DAS28-ESR and CDAS or SADI,
although Spearman coefficient of correlation was always
higher (Fig. 2c, d).
During the initial phase of TCZ treatment, rheumatolo-
gists frequently observe a rapid decrease in inflammatory
markers, such as CRP and ESR, while the arthritis shows a
more gradual improvement. To determine whether or not the
DAS28-ESR and the other indices may become separated in
the relatively early phase of the TCZ treatment, we also
examined the correlation between DAS28-ESR and CDAI/
SDAI at weeks 4, 8, and 12 (Fig. 3; Table 1). The Spearman
coefficient of correlation between DAS28-ESR and CDAI
was almost constant during the treatment period, and there
was no significant decrease in week 4 or 8. The data were
essentially the same as those between DAS28-ESR and
SDAI in the TCZ treatment and those in the control MTX
treatment (Table 1). The same results were also obtained
from DAS28-CRP and CDAI and SDAI (data not shown).
Comparison between DAS28-ESR remission and CDAI
or SDAI remission
Although DAS28-ESR well correlated with CDAI and
SDAI, the rate of remission based on the DAS28-ESR
Fig. 3 Scatter plots of DAS28-ESR versus CDAI/SDAI at weeks 4, 8,
and 12 in the TCZ group. The results of 58 patients at week 4, 60 patients
at week 8, and 59 patients at week 12 in the TCZ group are shown. The
difference in patient numbers is due to missing ESR data. All regression
lines indicate a highly significant correlation between DAS28-ESR and
CDAI/SDAI. a DAS28-ESR vs. CDAI (week 4, 8, 12), b DAS28-ESR vs.
SDAI (week 4, 8, 12)
Table 1 Spearman coefficient of correlation between DAS28-ESR
and CDAI or SDAI during treatment with TCZ or MTX
Indices of disease
activity
Weeks after the first treatment
0 4 8 12 24
DAS28-ESR vs. CDAI
TCZ 0.818 0.842 0.822 0.890 0.823
MTX 0.883 0.865 0.911 0.921 0.887
DAS28-ESR vs. SDAI
TCZ 0.854 0.861 0.831 0.900 0.838
MTX 0.893 0.869 0.902 0.930 0.897
DAS28-ESR 28-joint disease activity score using erythrocyte sedi-
mentation rate, CDAI, SDAI, clinical and simplified disease activity
indices, respectively, TCZ tocilizumab, MTX methotrexate
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was quite different from that based on the CDAI and
SDAI, respectively. At week 24, DAS28-ESR remission
was attained in 47.2% of the patients, even though the
CDAI and SDAI remission rates were only 15.1 and
17.0%, respectively (Table 2). To explore the reasons for
the difference in these rates, we examined the charac-
teristics of the patients who were in remission according
to the DAS28 (‘‘remitters’’) but not according to the
CDAI or SDAI. Among the 17 patients who were in
DAS28 remission but not CDAI remission, six patients
(35.3%) had a SJC C 4 and five patients (31.5%) had a
high patient global score ([3 cm; Fig. 4). In contrast,
CDAI remitters generally had low scores on all mea-
surements, and joint swelling and tenderness improved
in most of these patients (Table 2). The same results
were obtained when the distribution of each component
of SDAI was analysed in the patients who attained
DAS28 remission but not SDAI remission (Fig. 5;
Table 2).
In the control (TCZ placebo plus MTX 8 mg/week)
group, only one patient (1.6%) achieved even DAS28-ESR
remission; this patient also achieved CDAI and SDAI
remission. The number was too small and, therefore, a
similar analysis was not available.
Table 2 Remission and clinical
variables in the tocilizumab-
treated group of the SATORI
study at week 24
SJC swollen joint count, TJC
tender joint count
Variable n (%)
DAS28-ESR \ 2.6 (% of patients who participated in the full 24-week study) 25 (47.2)
SJC in 28 joints = 0 in DAS remitters (% in DAS remitters) 11 (44.0)
TJC in 28 joints = 0 in DAS remitters (% in DAS remitters) 17 (68.0)
SJC ? TJC in 28 joints B 1 in DAS remitters (% in DAS remitters) 12 (48.0)
CDAI \ 2.8 (% of patients who participated in the full 24-week study) 8 (15.1)
SJC in 28 joints = 0 in CDAI remitters (% in CDAI remitters) 7 (87.5)
TJC in 28 joints = 0 in CDAI remitters (% in CDAI remitters) 8 (100)
SJC ? TJC in 28 joints B 1 in CDAI remitters (% in CDAI remitters) 7 (87.5)
SDAI \ 3.3 (% of patients who participated in the full 24-week study) 9 (17.0)
SJC in 28 joints = 0 in SDAI remitters (% in SDAI remitters) 8 (88.9)
TJC in 28 joints = 0 in SDAI remitters (% in SDAI remitters) 9 (100)
SJC ? TJC in 28 joints B 1 in SDAI remitters (% in SDAI remitters) 8 (88.9)
Fig. 4 Histograms of CDAI
remission variables in the 17
patients who were in remission
according to the DAS28 but not
according to the CDAI
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Correlation between ACR response category
and changes in DAS28, CDAI and SDAI
Among the TCZ-treated patients who completed the 24-
week study, the ACR20, ACR50 and ACR70 response
rates at week 24 were 83.0 (44/53), 54.7 (29/53) and 32.1%
(17/53), respectively. The CDAI and SDAI remitters (8 and
10 patients, respectively) all achieved ACR70. However,
among the 25 DAS28-ESR remitters, 17 (68%) achieved
ACR70, three achieved ACR50 and five achieved only
ACR20. No patient achieved DAS28-ESR remission
without achieving at least ACR20. Among the DAS28-
ESR remitters who achieved ACR70, the maximum
DAS28-ESR score was 2.43.
Discussion
To compare the validity of methods of evaluating the anti-
rheumatic effects of TCZ, an IL-6 receptor inhibitor that
significantly reduces the level of inflammatory markers
such as ESR and CRP, we investigated the correlations
between DAS28-ESR and other methods for evaluating RA
disease activity, namely, CDAI, SDAI and the ACR core
set response category.
We found that the Spearman coefficient of correlation
between DAS28-ESR and CDAI (whose formula does not
include any inflammatory markers) at week 24 was [0.8
and that this correlation coefficient was comparable to
those determined at baseline and weeks 4, 8, and 12,
respectively. There was no decrease in the correlation
coefficient related to the rapid improvement of ESR after
the introduction of TCZ treatment. The same results were
obtained when we compared the Spearman coefficient of
correlation between DAS28-ESR and SDAI (whose for-
mula includes the CRP level). The coefficients of correla-
tion between DAS28-ESR and SDAI were also always
[0.8. These results suggest that the DAS28-ESR score is
not markedly lowered by the sudden decrease in ESR that
occurs during the first 4 weeks of treatment with TCZ.
Shaver et al. [24] examined the correlation coefficient
between DAS28 and CDAI among RA patients in the
setting of a community rheumatology practice. Although
all of the patients enrolled in their study did not receive
TCZ treatment because TCZ had not yet been launched in
the USA during the study period, the correlation coefficient
obtained between these two indices was quite similar to our
result. These researchers also reported that there was a
large difference between the remission rate based on the
DAS28 and that based on the CDAI and that only about
30% of DAS remitters could attain CDAI remission. The
CDAI remitter and DAS remitter rates in our study were
comparable with the respective rates in their study. These
results suggest that a difference between DAS remission
and CDAI remission is not specific to TCZ treatment, i.e.,
this difference was accrued due to the distinction in the
definition of remission criterion in the DAS28-ESR and
CDAI. These results also suggest that DAS28-ESR is as
Fig. 5 Histograms of SDAI
remission variables in the 16
patients who attained remission
according to the DAS28 but not
according to the SDAI
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useful as CDAI in terms of evaluating the efficacy of TCZ
and other anti-rheumatic drugs that have strong inhibiting
effects on inflammatory markers.
Figure 4 provides insight into the factors responsible for
the difference in remission rates according to the CDAI and
DAS28 scales. Many of our patients who satisfied the
DAS28 remission criteria but not the CDAI remission
criteria had a high SJC and high PGA score. By nature of
the definition of CDAI, CDAI remission patients generally
had low scores on all of the incorporated measures. The
same results were obtained when the difference in the
remission rates according to the SDAI and DAS28 scales
was analyzed even though the formula for SDAI includes
the CRP level as a component for assessing remission
(Fig. 5).
A difference between DAS28-ESR and CDAI or SDAI
remission among ACR response rates was also observed.
All CDAI and SDAI remitters achieved ACR70, but
among the 25 DAS28-ESR remitters, 17 (61%) achieved
ACR70 while the others achieved no more than ACR50
or ACR20. Since all SDAI remitters achieved ACR70
even though the formula for SDAI includes an inflam-
matory marker (CRP), we concluded that the difference
between the numbers of DAS28-ESR remitters and
ACR70 responders was not caused by the inclusion of
ESR in DAS28-ESR, but by the remission criterion used
in the DAS28-ESR method. Sokka et al. [25] compared
the performance of different definitions of remission,
including DAS28, CDAI and ACR criteria. They con-
cluded that the use of different definitions of RA remis-
sion leads to different results with regard to remission rate
and that the rates of remission defined as ‘‘DAS28-
ESR \ 2.6’’ are higher than those defined by other means.
Ma¨kinen et al. [26] suggested that a stricter criterion
(DAS28-ESR \ 2.32) is appropriate for defining DAS28-
ESR remission. Using the stricter criterion suggested by
Ma¨kinen et al., all patients with DAS28-ESR \2.32 in the
SATORI study achieved ACR70.
In conclusion, our results confirm that DAS28-ESR has
a validity comparable to that of other methods in terms of
evaluating the RA treatment efficacy of TCZ, even though
this drug strongly inhibits inflammatory markers.
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